Bremelanotide

Sexual Health

Also known as: PT-141, Vyleesi

A melanocortin receptor agonist FDA-approved for hypoactive sexual desire disorder in premenopausal women.

Dose in studies
1-2 mg as needed
Frequency
As needed, max 8 doses/month
Cycle length
As needed, no cycling required
Half-life
2.7 hours
Research level
4/5 – Well researched

Bremelanotide dosage chart

Frequently asked questions about Bremelanotide

What is Bremelanotide?

A melanocortin receptor agonist FDA-approved for hypoactive sexual desire disorder in premenopausal women.

What is the half-life of Bremelanotide?

The half-life of Bremelanotide is 2.7 hours.

What dosage of Bremelanotide has been studied?

Described in research: 1-2 mg as needed, frequency: As needed, max 8 doses/month. This is not a medical recommendation.

How long is a Bremelanotide cycle?

Typical cycle length in studies: As needed, no cycling required.

What are the side effects of Bremelanotide?

Nausea: Most common side effect (~40%). Can be significant with first dose. Anti-nausea pre-treatment (ondansetron) recommended. Severity typically decreases with repeated use. · Flushing: Facial warmth and redness lasting 1-3 hours. More pronounced than with PT-141. Harmless. · Headache: Moderate headache in ~10% of users. Standard analgesics effective. · Injection site reactions: Mild redness…

How well researched is Bremelanotide?

Well researched (4/5). Large phase 3 trials or regulatory approval; long-term data still limited.